UNSPSC 51101938: Tebuquine

This classification denotes an antimalarial agent with the molecular formula C26H25Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 699Q1XT4EN, chemically known as wr 228,258 but generally known as tebuquine, which bears US NIH Compound Identifier 71991. European Medicines Agency schedules Tebuquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10855MIG. The term TEBUQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23).

UNSPSC 51101938 Tebuquine, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two opportunities tagged to this code in recent months—a pharmaceutical warehouse supply contract for antibiotics (Doxycycline and Ciprofloxacin) and a procurement for Naloxone and drug deactivation systems—do not represent purchases of tebuquine itself. State and local buyers are instead sourcing other pharmaceutical products through cooperative purchasing vehicles and direct procurement channels, suggesting either that tebuquine has limited use in state and local health or emergency-response contexts, or that purchases under this code are rare enough to surface few recent opportunities.

The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for antibiotic supply, while Seminole County, Florida issued an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building. Neither solicitation targets tebuquine. Buyers under this code appear concentrated among health departments and county public-health or emergency-services agencies, with activity visible in Florida and Illinois, though the broader geographic distribution and issuing-body concentration cannot be established from these misaligned records. Business development professionals should verify whether tebuquine demand exists in their target markets or whether opportunities in this code are best monitored as part of a broader pharmaceutical or emergency-response portfolio rather than pursued as a standalone line of business.